Press release
Mucopolysaccharidosis Type I Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Mucopolysaccharidosis Type I Pipeline. Dive into DelveInsight's comprehensive report today! @ Mucopolysaccharidosis Type I Pipeline Outlook [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Mucopolysaccharidosis Type I Pipeline Report
* In May 2025, JCR Pharmaceuticals Co. Ltd announced a JR-171-101 study (NCT04227600) and fulfill all eligibility criteria can be enrolled in this JR-171-102 study. In the JR-171-102 study, subjects will receive either 2.0 or 4.0 mg/kg/week of JR-171 intravenously at the same doses received at Week 12 of the JR-171-101 study.
* DelveInsight's Mucopolysaccharidosis Type I Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Mucopolysaccharidosis Type I treatment.
* The leading Mucopolysaccharidosis Type I Companies such as Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
* Promising Mucopolysaccharidosis Type I Pipeline Therapies such as Laronidase, Antihistamine, Antipyretic, JR-171, AGT-181, Cyclosporine A (CsA), Azathioprine (Aza), RGX-111, SBC-103 , and others.
Stay ahead with the most recent pipeline outlook for Mucopolysaccharidosis Type I. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Mucopolysaccharidosis Type I Treatment Drugs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mucopolysaccharidosis Type I Emerging Drugs Profile
* OTL 203: Orchard Therapeutics
OTL-203 is an investigational ex vivo autologous gene therapy being investigated for the treatment of MPS-I. It uses a modified virus to insert a functional copy of the IDUA gene into a patient's cells. OTL-203 is being developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. OTL-203 has received rare pediatric disease designation from the FDA. Through an ongoing proof-of-concept clinical trial, OTL-203 is being evaluated as a potential treatment for patients with the most severe form of MPS-I, known as Hurler syndrome. OTL-203 is an investigational therapy and has not been approved by any regulatory agency or health authority. Currently, the drug is in Phase III stage of its development for the treatment of Mucopolysaccharidosis Type I.
* JR 171: JCR Pharmaceuticals
JR-171, is an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome). JR-171 is a blood-brain-barrier (BBB)-penetrating form recombinant -L-iduronidase that was developed using JCR's proprietary J-Brain Cargo Registered BBB technology. JR-171 received the orphan drug designation from the US Food Drug Administration (FDA) in February 2021. The trial is also scheduled for enrolling patients in the US. Currently, the drug is in Phase I/II stage of its development for the treatment of Mucopolysaccharidosis Type I.
The Mucopolysaccharidosis Type I Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Mucopolysaccharidosis Type I with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mucopolysaccharidosis Type I Treatment.
* Mucopolysaccharidosis Type I Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Mucopolysaccharidosis Type I Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mucopolysaccharidosis Type I market
Explore groundbreaking therapies and clinical trials in the Mucopolysaccharidosis Type I Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Mucopolysaccharidosis Type I Drugs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mucopolysaccharidosis Type I Companies
Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
Mucopolysaccharidosis type I (MPS I) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Mucopolysaccharidosis Type I Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Mucopolysaccharidosis Type I Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Mucopolysaccharidosis Type I Market Drivers and Barriers [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Mucopolysaccharidosis Type I Market Report
* Coverage- Global
* Mucopolysaccharidosis Type I Companies- Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
* Mucopolysaccharidosis Type I Pipeline Therapies- Laronidase, Antihistamine, Antipyretic, JR-171, AGT-181, Cyclosporine A (CsA), Azathioprine (Aza), RGX-111, SBC-103 , and others.
* Mucopolysaccharidosis Type I Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mucopolysaccharidosis Type I Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Mucopolysaccharidosis Type I Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mucopolysaccharidosis Type I Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Mucopolysaccharidosis type I (MPS I): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mucopolysaccharidosis type I (MPS I)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* OTL 203: Orchard Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* JR 171: JCR Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Mucopolysaccharidosis type I (MPS I) Key Companies
* Mucopolysaccharidosis type I (MPS I) Key Products
* Mucopolysaccharidosis type I (MPS I)- Unmet Needs
* Mucopolysaccharidosis type I (MPS I)- Market Drivers and Barriers
* Mucopolysaccharidosis type I (MPS I)- Future Perspectives and Conclusion
* Mucopolysaccharidosis type I (MPS I) Analyst Views
* Mucopolysaccharidosis type I (MPS I) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mucopolysaccharidosis-type-i-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/mucopolysaccharidosis-type-i-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Type I Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4026998 • Views: …
More Releases from ABNewswire
Arizona Startup Revolutionizes Family Memories with QR Code-Enabled Photo Magnet …
Magnet Maker Studio LLC launches innovative photo magnets featuring QR codes that transform refrigerators into interactive family galleries. The Arizona-based, faith-inspired company enables customers to attach personal videos and messages to physical keepsakes, bridging digital and tangible memories.
Magnet Maker Studio LLC, a newly launched Arizona-based company, is revolutionizing how families preserve and share memories through innovative photo magnets that seamlessly blend physical keepsakes with digital storytelling. The family-owned business has…
Mesquite Renovations LLC Transforms Healthcare Facilities in Midland, Enhancing …
Mesquite Renovations LLC is transforming healthcare facilities in Midland, improving patient care and access with cutting-edge renovations for modern medical environments.
Midland, TX - Mesquite Renovations LLC, a leading healthcare facility construction Midland TX [https://mesquiterenovations.com/medical-facility-renovations/], is proud to announce the successful transformation of several healthcare facilities in Midland, improving both patient care and overall access to medical services. With a commitment to excellence, Mesquite Renovations continues to set the standard in…
DigiGary Marketing Partners with Dallas Events to Maximize Digital Reach and Eng …
DigiGary Marketing partners with Dallas Events to enhance their digital presence, optimizing engagement and expanding reach for local events and businesses.
Dallas, TX - DigiGary Marketing, a leading digital marketing agency in Dallas [https://www.digigary.com/], is excited to announce its new strategic partnership with Dallas Events, one of the city's foremost event organizers. This collaboration is designed to leverage the power of advanced digital marketing strategies to enhance the reach, visibility, and…
Nework Brings Entertainment Everywhere with Battery-Powered Portable TV Early Bi …
From kitchen to living room, the Nework MoveMate AI 27" Portable TV redefines how users work, learn, and play.
Los Angeles, CA - Nov 11, 2025 - Enjoying favorite streaming shows, YouTube/Tiktok Shorts, and instructional videos shouldn't only be in one room. Innovative brand leader Nework has unveiled the MoveMate AI 27" Portable TV, a battery-powered entertainment and productivity device built for modern life on the move.
Image: https://www.abnewswire.com/upload/2025/11/5210dc5fe865e7cc4c5e8fdbbe7822fc.jpg
Backed by the interactive…
More Releases for Mucopolysaccharidosis
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Mucopolysaccharidosis Market Set to Hit USD 3.65 Billion by 2034
Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the absence or malfunction of enzymes needed to break down glycosaminoglycans (GAGs). These conditions, including Hurler syndrome (MPS I), Hunter syndrome (MPS II), Sanfilippo syndrome (MPS III), and others, are progressive and can affect physical and cognitive development.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71067
Over the past decade, orphan drug development, advancements in enzyme replacement therapy…
Mucopolysaccharidosis Treatment Market: A Robust Growth Driven by Advancements a …
Understanding the Steady Rise in Global Mucopolysaccharidosis Treatment Market: Focus on Market Size and Growth Rate
- The mucopolysaccharidosis treatment market demonstrated strong growth in recent times, increasing from $2.4 billion in 2024 to an expected $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%.
- The growth in this historic period is primarily backed by initiatives such as enzyme replacement therapy (ERT), improved diagnostic tools, focused advocacy…
Mucopolysaccharidosis Treatment Market Analysis, Keyplayers, Share And Forecast …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Mucopolysaccharidosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.19 billion In 2028 At…
Mucopolysaccharidosis Treatment Market Size, Trends, Leading Players, Share And …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Mucopolysaccharidosis Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The mucopolysaccharidosis treatment market size has grown strongly in recent years. It…
Gene Therapy for Mucopolysaccharidosis Market to Witness Growth Acceleration by …
Gene Therapy for Mucopolysaccharidosis Market is expected to witness moderate growth registering 9.4% CAGR during the forecast period (2023-2029).
Important changes in the business allow key players to attain larger profits. This Gene Therapy for Mucopolysaccharidosis Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry. Furthermore, this market report makes…
